EGFR and non-small cell lung carcinoma: It has been shown that combinations of HDAC inhibitor such as vorinostat, panobinostat, and EGFR-TKIs to overcome EGFR-TKI resistance is associated with the BIM polymorphism in EGFR-mutant NSCLC (38, 39).